Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Przepiorka D et al. | Tacrolimus for prevention of graft-versus-host disease after mismatched unrelated donor cord blood transplantation. | 1999 | Bone Marrow Transplant. | pmid:10414918 |
Varghese Z et al. | Calcineurin inhibitors enhance low-density lipoprotein oxidation in transplant patients. | 1999 | Kidney Int. Suppl. | pmid:10412758 |
Muegge I et al. | Evaluation of PMF scoring in docking weak ligands to the FK506 binding protein. | 1999 | J. Med. Chem. | pmid:10411471 |
Rhew JH et al. | Induction of fibronectin gene expression by inhibitors of protein phosphatase type 2B in normal and transformed fibroblasts. | 1999 | Exp. Mol. Med. | pmid:10410305 |
Hebert MF and Lam AY | Diltiazem increases tacrolimus concentrations. | 1999 | Ann Pharmacother | pmid:10410178 |
Kaibori M et al. | Immunosuppressant FK506 inhibits inducible nitric oxide synthase gene expression at a step of NF-kappaB activation in rat hepatocytes. | 1999 | J. Hepatol. | pmid:10406194 |
Banerjee C et al. | Ca2+ and calmodulin-dependent protein phosphatase from Leishmania donovani. | 1999 | Parasitology | pmid:10406035 |
Timmermann W et al. | Videomicroscopic imaging of graft mucosa for monitoring immunosuppressive therapy after small intestinal transplantation in rats. | 1999 | Transplantation | pmid:10401762 |
Tada H et al. | Role of diltiazem on tacrolimus pharmacokinetics in tacrolimus-induced nephrotoxic rats. | 1999 | Pharmacol. Toxicol. | pmid:10401724 |
Katayama Y | [Current tendency in treatment for acute ischemic stroke]. | 1999 | Nippon Ika Daigaku Zasshi | pmid:10401232 |
Haas M et al. | Smooth muscle-specific actin levels in the urine of renal transplant recipients: correlation with cyclosporine or tacrolimus nephrotoxicity. | 1999 | Am. J. Kidney Dis. | pmid:10401019 |
Gold BG et al. | Efficacy of delayed or discontinuous FK506 administrations on nerve regeneration in the rat sciatic nerve crush model: lack of evidence for a conditioning lesion-like effect. | 1999 | Neurosci. Lett. | pmid:10400242 |
Magee CC et al. | Immunosuppressive agents in organ transplantation. | 1999 | Hosp Med | pmid:10396414 |
Kochi S et al. | Effect of cyclosporin A or tacrolimus on the function of blood-brain barrier cells. | 1999 | Eur. J. Pharmacol. | pmid:10395024 |
Horowitz MM et al. | Tacrolimus vs. cyclosporine immunosuppression: results in advanced-stage disease compared with historical controls treated exclusively with cyclosporine. | 1999 | Biol. Blood Marrow Transplant. | pmid:10392964 |
Hasselder AS | The nursing management of a patient receiving Prograf as a primary immunosuppressive agent. | 1998 Apr-Jun | EDTNA ERCA J | pmid:10392057 |
Liang H et al. | Regulation of angiotensin II-induced phosphorylation of STAT3 in vascular smooth muscle cells. | 1999 | J. Biol. Chem. | pmid:10391929 |
Gerhardt U et al. | Blood pressure control in kidney transplant recipients: influence of immunosuppression. | 1999 | J Auton Pharmacol | pmid:10385269 |
Squadrito F et al. | Tacrolimus suppresses tumour necrosis factor-alpha and protects against splanchnic artery occlusion shock. | 1999 | Br. J. Pharmacol. | pmid:10385251 |
Leung W et al. | Long-term complete remission and immune tolerance after intensive chemotherapy for lymphoproliferative disorders complicating liver transplant. | 1999 | Transplantation | pmid:10385092 |